Prevalence estimates of polycystic kidney and liver disease by population sequencing

Matthew B. Lanktree, Amirreza Haghighi, Elsa Guiard, Ioan Andrei Iliuta, Xuewen Song, Peter C Harris, Andrew D. Paterson, York Pei

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background Estimating the prevalence of autosomal dominant polycystic kidney disease (ADPKD) is challenging because of age-dependent penetrance and incomplete clinical ascertainment. Early studies estimated the lifetime risk of ADPKD to be about one per 1000 in the general population, whereas recent epidemiologic studies report a point prevalence of three to five cases per 10,000 in the general population. Methods To measure the frequency of high-confidence mutations presumed to be causative in ADPKD and autosomal dominant polycystic liver disease (ADPLD) and estimate lifetime ADPKD prevalence, we used two large, population sequencing databases, gnomAD (15,496 whole-genome sequences; 123,136 exome sequences) and BRAVO (62,784 whole-genome sequences). We used stringent criteria for defining rare variants in genes involved in ADPKD (PKD1, PKD2), ADPLD (PRKCSH, SEC63, GANAB, ALG8, SEC61B, LRP5), and potential cystic disease modifiers; evaluated variants for quality and annotation; compared variants with data from an ADPKD mutation database; and used bioinformatic tools to predict pathogenicity. Results Identification of high-confidence pathogenic mutations in whole-genome sequencing provided a lower boundary for lifetime ADPKD prevalence of 9.3 cases per 10,000 sequenced. Estimates from whole-genome and exome data were similar. Truncating mutations in ADPLD genes and genes of potential relevance as cyst modifiers were found in 20.2 cases and 103.9 cases per 10,000 sequenced, respectively. Conclusions Population whole-genome sequencing suggests a higher than expected prevalence of ADPKD-associated mutations. Loss-of-function mutations in ADPLD genes are also more common than expected, suggesting the possibility of unrecognized cases and incomplete penetrance. Substantial rare variation exists in genes with potential for phenotype modification in ADPKD.

Original languageEnglish (US)
Pages (from-to)2593-2600
Number of pages8
JournalJournal of the American Society of Nephrology
Volume29
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Autosomal Dominant Polycystic Kidney
Polycystic Kidney Diseases
Population
Mutation
Genome
Exome
Penetrance
Genes
Databases
Polycystic liver disease
Computational Biology
Virulence
Cysts
Epidemiologic Studies
Phenotype

ASJC Scopus subject areas

  • Nephrology

Cite this

Prevalence estimates of polycystic kidney and liver disease by population sequencing. / Lanktree, Matthew B.; Haghighi, Amirreza; Guiard, Elsa; Iliuta, Ioan Andrei; Song, Xuewen; Harris, Peter C; Paterson, Andrew D.; Pei, York.

In: Journal of the American Society of Nephrology, Vol. 29, No. 10, 01.10.2018, p. 2593-2600.

Research output: Contribution to journalArticle

Lanktree, MB, Haghighi, A, Guiard, E, Iliuta, IA, Song, X, Harris, PC, Paterson, AD & Pei, Y 2018, 'Prevalence estimates of polycystic kidney and liver disease by population sequencing', Journal of the American Society of Nephrology, vol. 29, no. 10, pp. 2593-2600. https://doi.org/10.1681/ASN.2018050493
Lanktree, Matthew B. ; Haghighi, Amirreza ; Guiard, Elsa ; Iliuta, Ioan Andrei ; Song, Xuewen ; Harris, Peter C ; Paterson, Andrew D. ; Pei, York. / Prevalence estimates of polycystic kidney and liver disease by population sequencing. In: Journal of the American Society of Nephrology. 2018 ; Vol. 29, No. 10. pp. 2593-2600.
@article{82e5d4a3ffe34c28a081a8bfe08c45e0,
title = "Prevalence estimates of polycystic kidney and liver disease by population sequencing",
abstract = "Background Estimating the prevalence of autosomal dominant polycystic kidney disease (ADPKD) is challenging because of age-dependent penetrance and incomplete clinical ascertainment. Early studies estimated the lifetime risk of ADPKD to be about one per 1000 in the general population, whereas recent epidemiologic studies report a point prevalence of three to five cases per 10,000 in the general population. Methods To measure the frequency of high-confidence mutations presumed to be causative in ADPKD and autosomal dominant polycystic liver disease (ADPLD) and estimate lifetime ADPKD prevalence, we used two large, population sequencing databases, gnomAD (15,496 whole-genome sequences; 123,136 exome sequences) and BRAVO (62,784 whole-genome sequences). We used stringent criteria for defining rare variants in genes involved in ADPKD (PKD1, PKD2), ADPLD (PRKCSH, SEC63, GANAB, ALG8, SEC61B, LRP5), and potential cystic disease modifiers; evaluated variants for quality and annotation; compared variants with data from an ADPKD mutation database; and used bioinformatic tools to predict pathogenicity. Results Identification of high-confidence pathogenic mutations in whole-genome sequencing provided a lower boundary for lifetime ADPKD prevalence of 9.3 cases per 10,000 sequenced. Estimates from whole-genome and exome data were similar. Truncating mutations in ADPLD genes and genes of potential relevance as cyst modifiers were found in 20.2 cases and 103.9 cases per 10,000 sequenced, respectively. Conclusions Population whole-genome sequencing suggests a higher than expected prevalence of ADPKD-associated mutations. Loss-of-function mutations in ADPLD genes are also more common than expected, suggesting the possibility of unrecognized cases and incomplete penetrance. Substantial rare variation exists in genes with potential for phenotype modification in ADPKD.",
author = "Lanktree, {Matthew B.} and Amirreza Haghighi and Elsa Guiard and Iliuta, {Ioan Andrei} and Xuewen Song and Harris, {Peter C} and Paterson, {Andrew D.} and York Pei",
year = "2018",
month = "10",
day = "1",
doi = "10.1681/ASN.2018050493",
language = "English (US)",
volume = "29",
pages = "2593--2600",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "10",

}

TY - JOUR

T1 - Prevalence estimates of polycystic kidney and liver disease by population sequencing

AU - Lanktree, Matthew B.

AU - Haghighi, Amirreza

AU - Guiard, Elsa

AU - Iliuta, Ioan Andrei

AU - Song, Xuewen

AU - Harris, Peter C

AU - Paterson, Andrew D.

AU - Pei, York

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background Estimating the prevalence of autosomal dominant polycystic kidney disease (ADPKD) is challenging because of age-dependent penetrance and incomplete clinical ascertainment. Early studies estimated the lifetime risk of ADPKD to be about one per 1000 in the general population, whereas recent epidemiologic studies report a point prevalence of three to five cases per 10,000 in the general population. Methods To measure the frequency of high-confidence mutations presumed to be causative in ADPKD and autosomal dominant polycystic liver disease (ADPLD) and estimate lifetime ADPKD prevalence, we used two large, population sequencing databases, gnomAD (15,496 whole-genome sequences; 123,136 exome sequences) and BRAVO (62,784 whole-genome sequences). We used stringent criteria for defining rare variants in genes involved in ADPKD (PKD1, PKD2), ADPLD (PRKCSH, SEC63, GANAB, ALG8, SEC61B, LRP5), and potential cystic disease modifiers; evaluated variants for quality and annotation; compared variants with data from an ADPKD mutation database; and used bioinformatic tools to predict pathogenicity. Results Identification of high-confidence pathogenic mutations in whole-genome sequencing provided a lower boundary for lifetime ADPKD prevalence of 9.3 cases per 10,000 sequenced. Estimates from whole-genome and exome data were similar. Truncating mutations in ADPLD genes and genes of potential relevance as cyst modifiers were found in 20.2 cases and 103.9 cases per 10,000 sequenced, respectively. Conclusions Population whole-genome sequencing suggests a higher than expected prevalence of ADPKD-associated mutations. Loss-of-function mutations in ADPLD genes are also more common than expected, suggesting the possibility of unrecognized cases and incomplete penetrance. Substantial rare variation exists in genes with potential for phenotype modification in ADPKD.

AB - Background Estimating the prevalence of autosomal dominant polycystic kidney disease (ADPKD) is challenging because of age-dependent penetrance and incomplete clinical ascertainment. Early studies estimated the lifetime risk of ADPKD to be about one per 1000 in the general population, whereas recent epidemiologic studies report a point prevalence of three to five cases per 10,000 in the general population. Methods To measure the frequency of high-confidence mutations presumed to be causative in ADPKD and autosomal dominant polycystic liver disease (ADPLD) and estimate lifetime ADPKD prevalence, we used two large, population sequencing databases, gnomAD (15,496 whole-genome sequences; 123,136 exome sequences) and BRAVO (62,784 whole-genome sequences). We used stringent criteria for defining rare variants in genes involved in ADPKD (PKD1, PKD2), ADPLD (PRKCSH, SEC63, GANAB, ALG8, SEC61B, LRP5), and potential cystic disease modifiers; evaluated variants for quality and annotation; compared variants with data from an ADPKD mutation database; and used bioinformatic tools to predict pathogenicity. Results Identification of high-confidence pathogenic mutations in whole-genome sequencing provided a lower boundary for lifetime ADPKD prevalence of 9.3 cases per 10,000 sequenced. Estimates from whole-genome and exome data were similar. Truncating mutations in ADPLD genes and genes of potential relevance as cyst modifiers were found in 20.2 cases and 103.9 cases per 10,000 sequenced, respectively. Conclusions Population whole-genome sequencing suggests a higher than expected prevalence of ADPKD-associated mutations. Loss-of-function mutations in ADPLD genes are also more common than expected, suggesting the possibility of unrecognized cases and incomplete penetrance. Substantial rare variation exists in genes with potential for phenotype modification in ADPKD.

UR - http://www.scopus.com/inward/record.url?scp=85054312308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054312308&partnerID=8YFLogxK

U2 - 10.1681/ASN.2018050493

DO - 10.1681/ASN.2018050493

M3 - Article

C2 - 30135240

AN - SCOPUS:85054312308

VL - 29

SP - 2593

EP - 2600

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 10

ER -